Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Opioid-Related Disorders: early-phase trial registry
8 of 59 indexed Opioid-Related Disorders trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #241 of 28,707 conditions by registered trial count.
59 US clinical trials · 8 currently recruiting · #241 of 28,707 conditions by registered trial count
Opioid-Related Disorders: 59 US clinical trials tracked, 8 recruiting.
Opioid-Related Disorders is the subject of 59 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 25 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute on Drug Abuse (NIDA), running 10 of these trials.
Enrollment posture brief
Registry condition opioid-related-disorders
OPEN 8 | RECR 14% | LATE 10 | EARLY 25 | RANK #241 | SPON 10
Volume-matched condition peers
Nearest open-share peer: Chronic Myeloproliferative Disorders (14% recruiting · 22 trials)
Opioid-Related Disorders lists 8 open slots (14% of 59 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Opioid-Related Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Opioid-Related Disorders is recruiting below its size-band peers.
8 of 59 indexed trials (13.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Opioid-Related Disorders research.
National Institute on Drug Abuse (NIDA) accounts for 10 of 59 trials (16.9%). 38 distinct sponsors appear on at least one study for this condition label.
-
Typical Opioid-Related Disorders enrolment sits around 140 participants.
Median target enrolment is 140 among the 48 trials that report a genuine target (sentinel values excluded). 22 of those (45.8%) plan for fewer than 100 participants.
-
Opioid-Related Disorders research is mostly interventional.
52 interventional and 7 observational studies make up this index (88.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
59 total, page 1 of 2
Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care
University of Pittsburgh
NCT06810076
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
University of Utah
NCT06387290
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
University of Arkansas
NCT05336188
fMRI and Opioid Abstinence
Yale University
NCT06651333
Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
National Institute on Drug Abuse (NIDA)
NCT03745339
Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment
VA Office of Research and Development
NCT06454903
STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
Indiana University
NCT05603702
Psilocybin in Cancer Pain Study
Yvan Beaussant, MD, MSci
NCT06001749
More Individualized Care: Assessment and Recovery Through Engagement
Kaiser Permanente
NCT05122676
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
April M Young
NCT05657106
Developing a Tailored Stigma Reduction Intervention to Increase Buprenorphine Prescribing
Ohio University
NCT05505227
Healthy Opioid Prescription Engagement
Jerry Cochran
NCT05141266
OUD Smartphone Services
Western Michigan University
NCT06134882
Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)
Yih-Ing Hser
NCT06023459
Tau PET Imaging in Opioid Use Disorder
University of Pennsylvania
NCT05651516
Feasibility of Deep Brain Stimulation as a Novel Treatment for Refractory Opioid Use Disorder
West Virginia University
NCT03950492
Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing
University of Washington
NCT03932799
Addressing Origins of the Opioid Epidemic by Improving Prescribing for Opioid-Naive Patients
Weill Medical College of Cornell University
NCT03377855
Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
Indivior
NCT02357901
An Observational Study of Environmental and SocioEconomic Factors in Opioid Recovery
Indivior
NCT03604861
The Kentucky Viral Hepatitis Treatment Study
Jennifer Havens
NCT03949764
Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence
Orexo AB
NCT01848054
Repeated-dose Behavioral Intervention to Reduce Opioid Overdose
San Francisco Department of Public Health
NCT03838510
Preventing Parental Opioid and/or Methamphetamine Addiction Within DHS-Involved Families: PRE-FAIR
Chestnut Health Systems
NCT05380440
Open-Label Treatment Extension Study
Indivior
NCT02896296
Safety & Prevention Outcomes Study
University of Michigan
NCT01894087
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
National Institute on Drug Abuse (NIDA)
NCT00000318
Treatment of Opioid/Heroin Dependence: Comparison of Three Medication Dosing Regimens
National Institute on Drug Abuse (NIDA)
NCT00218127
Medication Treatment for Opioid Use Disorder in Expectant Mothers
T. John Winhusen, PhD
NCT03918850
Treatment of Adult Attention Deficit Hyperactivity Disorder (ADHD) in Methadone Patients - 1
New York State Psychiatric Institute
NCT00061087
Medications Development for Drug Abuse Disorders
Johns Hopkins University
NCT01188421
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
T. John Winhusen, PhD
NCT03911466
Substance Use Treatment and Recovery Team (START)
RAND
NCT04314648
Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
T. John Winhusen, PhD
NCT03911739
Opioid Dependence Treatment Therapies in Pregnancy
University of Pittsburgh
NCT03098407
Transforming Opioid Prescribing in Primary Care
Boston Medical Center
NCT01909076
Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions
Roxane Laboratories
NCT00992095
Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
Acura Pharmaceuticals
NCT01759446
Neurocognitive Effects of Buprenorphine Among HIV+ and HIV-Opioid Users
Albert Einstein College of Medicine
NCT01108679
Induction of Opioid-Dependent Individuals Onto Buprenorphine and Buprenorphine/Naloxone
Indivior
NCT00637000
Study of Computer-Based Treatment for Drug Dependence
Yale University
NCT01315184
Buprenorphine Group Medical Visits in Primary Care
Montefiore Medical Center
NCT02526212
Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
Duke University
NCT02978417
Study to Evaluate the Subjective Effects of PTI-801 in Non-Physically Dependent Subjects With a History of Drug Abuse
Pain Therapeutics
NCT00734461
Methylnaltrexone for Opioid-induced Constipation in Cancer Patients
University of Vermont
NCT01004393
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
University of Chicago
NCT00000250
Reinforcing Effects of Brief Exposures to Nitrous Oxide - 8
University of Chicago
NCT00000256
A Laboratory Model for Heroin Abuse Medications - 8
New York State Psychiatric Institute
NCT00000273
Alternate-Day Buprenorphine Administration. Phase VII - 8
National Institute on Drug Abuse (NIDA)
NCT00000226
Alternate Day Buprenorphine Administration, Phase IX - 14
University of Vermont
NCT00000232
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 19 |
| Phase 3 | 7 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Opioid-Related Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Opioid-Related Disorders trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Opioid-Related Disorders page
59 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Opioid-Related Disorders trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute on Drug Abuse (NIDA) sponsors the most Opioid-Related Disorders trials on record, review their full trial history before evaluating a specific study. See National Institute on Drug Abuse (NIDA)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Opioid-Related Disorders condition card totals 59 registered trials; most-linked intervention Buprenorphine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.